ERBB2 and neoplasm: A landmark example of this mode of targeting is trastuzumab emtansine (T-DM1), an ADC that consists of a HER2-targeting trastuzumab with a microtubule inhibitor, enabling the precise delivery of cytotoxic therapy to HER2-overexpressing tumor cells while avoiding physiologically healthy tissue that does not express HER2 [115,116].